This is achieved by adding fenofibrate to simvastatin.
疗效是通过将非诺贝特加入辛伐他汀里取得的。
Objective: To improve synthetic route of simvastatin.
目的：合成降脂药辛伐他汀。
These limitations apply to ALL patients taking simvastatin.
这些限制适用于所有使用辛伐他汀的患者。
OBJECTIVE To study the dissolution rate in vitro of simvastatin pills.
目的探讨辛伐他汀滴丸的体外溶出速率。
Objective: To study the effects on lipid - lowing therapy of simvastatin.
前言：目的：探讨影响辛伐他汀降脂疗效的临床因素。
SEARCH also included data on muscle injury in patients taking simvastatin.
SEARCH同时包括患者服用辛伐他汀出现肌肉损伤的数据。
Both simvastatin and CDPC can relieve the damages of the brain in rats HIBD.
辛伐他汀和胞二磷胆碱可减轻新生大鼠hibd后脑组织损害。
The over expression could be blocked by arecoline, PPVP, DMHPPP and simvastatin.
槟榔碱、PPVP、DMHPPP和辛伐他汀可以减轻其过量表达。
Aim To compare the effects of different doses of simvastatin on decreasing blood-lipoids.
目的比较不同剂量辛伐他汀降血脂效果。
Simvastatin is sold as a single-ingredient generic medication and as the brand-name Zocor.
作为单一成分出售的辛伐他汀是非专利药，商品名为舒降之。
Objective: To understand the adverse effects of simvastatin and promote rational medication.
目的了解辛伐他汀的副作用，提倡合理用药。
Objective To examine the protective effects of simvastatin on articular cartilage in vitro.
目的探讨辛伐他汀对关节软骨的保护作用。
Objective To discuss the val ue of simvastatin plus fenofibrate for the treatment of mixed hyperlipemia.
目的探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的价值。
OBJECTIVE To prepare sustained-release dropping pills of Simvastatin and optimize its preparation technology.
目的制备辛伐他汀缓释滴丸并优化其制备工艺。
CONCLUSION: Simvastatin can decrease lipidemia, associated to the proteinuria decrease and the protection of renal function.
结论：辛伐他汀降血脂同时具有降蛋白尿和保护肾功能作用。
Conclusion Simvastatin may reduce TC and LDL-C, and meanwhile improves artery elasticity in patients with hypercholesterolemia.
结论辛伐他汀可明显降低高胆固醇血症患者TC和LDL - C，同时显著改善动脉弹性。
Conclusion: Simvastatin reveals the definite beneficial effect in treating the unstable angina and may get it in the early use.
结论：辛伐他汀在不稳定心绞痛治疗中，起着肯定的有益作用，并且早期应用可能即获益。
Objective To observe the influence of simvastatin on blood lipid and Creactive protein in patients with acute coronary syndrome.
目的：探讨早期应用辛伐他汀对急性冠脉综合征患者的血脂和C反应蛋白影响。
Objective To investigate the influences of simvastatin on carotid artery Intima-media thickness (IMT) and carotid atherosclerotic plaque.
目的探讨辛伐他汀对颈动脉内膜-中膜厚度及颈动脉粥样硬化斑块的影响。
OBJECTIVE To investigate the effect of simvastatin on biochemical markers of bone formation in treating the patients with hyperlipidemia.
目的研究辛伐他汀治疗高脂血症对骨形成生化标志物的影响。
There was no significant change of vasodilation responding to nitroglycerin and brachial diameter in all groups after simvastatin therapy.
辛伐他汀治疗后肱动脉内径和肱动脉对硝酸甘油的反应均无显著改变。
AIM: To probe the efficacy of simvastatin for lowering lipidemia in diabetic nephropathy with hyperlipidemia and protecting renal function.
目的：探索辛伐他汀对糖尿病肾病高脂血症降血脂疗效和保护肾功能的作用。
Conclusion Simvastatin can reduce the kidney hypertrophy index in the diabetic rats and it has renal protective effect on the diabetic rats.
结论辛伐他汀可以降低糖尿病大鼠肾肥大指数，对糖尿病肾脏病变有保护作用。
Objectives To investigate the effects of different dosage of simvastatin on acute myocardial infarction with paroxysmal atrial fibrillation.
目的探讨不同剂量辛伐他汀治疗急性心肌梗死合并阵发性心房颤动心脏复律后的近期疗效。
Conclusions Simvastatin, after 16 weeks of treatment, can be lower vascular obstruction, increase blood flow, and thus improve brain blood supply.
结论辛伐他汀治疗16周可以通过降低血管阻力增加血流量改善脑血管供血状态。
Objective: to observe the effects of early simvastatin intervention on endothelial vasodilator function in patients with acute coronary syndrome (ACS).
目的：探讨急性冠脉综合征(ACS)患者早期应用辛伐他汀后血管内皮功能的变化及其临床意义。
Objective To investigate the effect of simvastatin, ticlopidin and aspirin on the plasma plasminogen activitor inhibitor-l(PAI-1) contents in CHD patients.
目的研究辛伐他汀、抵克立得、阿司匹林对冠心病（CHD）患者血浆PAI-1含量的影响。
The risk of myopathy is also increased when simvastatin, especially at the higher doses, is used with certain drugs (see Simvastatin Dose Limitations below).
当辛伐他汀（特别是大剂量）与某些药物联合服用时，也会增加肌病的风险。
The study also confirmed that adding fenofibrate to simvastatin did not result in any excess risk of myopathy (muscle problems), venous thrombosis or pancreatitis.
这项研究同样证实将非诺贝特加入辛伐他汀不会引起任何肌病(肌肉病变)，静脉血栓或胰脏炎等多余危害。
The study also confirmed that adding fenofibrate to simvastatin did not result in any excess risk of myopathy (muscle problems), venous thrombosis or pancreatitis.
这项研究同样证实将非诺贝特加入辛伐他汀不会引起任何肌病(肌肉病变)，静脉血栓或胰脏炎等多余危害。
应用推荐